Imetelstat
- Generic Name
- Imetelstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C148H211N68O53P13S13
- CAS Number
- 868169-64-6
- Unique Ingredient Identifier
- F60NE4XB53
- Background
Imetelstat is under investigation in clinical trial NCT01916187 (Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Phase 2
Active, not recruiting
- Conditions
- Myelodysplastic SyndromesAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- GCP-Service International West GmbH
- Target Recruit Count
- 46
- Registration Number
- NCT05583552
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Royal Brisbane and Women's Hospitals, Brisbane, Australia
🇦🇺Linear Clinical Research, Nedlands, Australia
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
Phase 1
Withdrawn
- Conditions
- Solid TumorsLymphoma
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01568632
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath